These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6527237)

  • 1. Time-dependent elimination of cinoxacin in rats.
    Koike M; Norikura R; Mizojiri K; Sugeno K
    J Pharm Sci; 1984 Dec; 73(12):1697-700. PubMed ID: 6527237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of urinary pH on the pharmacokinetics of cinoxacin in humans and on antibacterial activity in vitro.
    Barbhaiya RH; Gerber AU; Craig WA; Welling PG
    Antimicrob Agents Chemother; 1982 Mar; 21(3):472-80. PubMed ID: 7103450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function.
    Maigaard S; Frimodt-Möller N; Welling PG; Madsen PO
    Antimicrob Agents Chemother; 1979 Sep; 16(3):411-6. PubMed ID: 507797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of probenecid on serum levels and urinary excretion of cinoxacin.
    Rodriguez N; Madsen PO; Welling PG
    Antimicrob Agents Chemother; 1979 Mar; 15(3):465-9. PubMed ID: 464575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinoxacin: mechanism of action, spectrum of activity, pharmacokinetics, adverse reactions, and therapeutic indications.
    Scavone JM; Gleckman RA; Fraser DG
    Pharmacotherapy; 1982; 2(5):266-72. PubMed ID: 6763208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral and intravenous trichloroethylene pharmacokinetics in the rat.
    D'Souza RW; Bruckner JV; Feldman S
    J Toxicol Environ Health; 1985; 15(5):587-601. PubMed ID: 4046066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein binding of quinolonecarboxylic acids. I. Cinoxacin, nalidixic acid and pipemidic acid.
    Izumi T; Kitagawa T
    Chem Pharm Bull (Tokyo); 1989 Mar; 37(3):742-5. PubMed ID: 2752487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinoxacin: competitive inhibitory effect on p-aminohippurate transport and its uptake in renal cortical slices.
    Gemba M; Komamura T; Matsushima Y; Itoh T; Miyata K; Nakamura M
    Arch Int Pharmacodyn Ther; 1983 Feb; 261(2):308-15. PubMed ID: 6838288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partition of cinoxacin and nalidixic acid in canine vascular and extravascular compartments.
    Szwed JJ; Redlich LR; Elliott RA; Kesler P; Black HR; Yu PL
    J Pharm Pharmacol; 1979 Aug; 31(8):567-8. PubMed ID: 40006
    [No Abstract]   [Full Text] [Related]  

  • 10. Toxicokinetics and bioavailability of oral and intravenous 1,1-dichloroethylene.
    Putcha L; Bruckner JV; D'Souza R; Desai F; Feldman S
    Fundam Appl Toxicol; 1986 Feb; 6(2):240-50. PubMed ID: 3699314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinoxacin in female mongrel dogs: effect of urine pH on urinary drug excretion and correlation of in vitro characteristics of oral dosage forms with bioavailability.
    Quay JF; Childers RF; Johnson DW; Nash JF; Stucky JF
    J Pharm Sci; 1979 Feb; 68(2):227-32. PubMed ID: 34019
    [No Abstract]   [Full Text] [Related]  

  • 12. Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections.
    Sisca TS; Heel RC; Romankiewicz JA
    Drugs; 1983 Jun; 25(6):544-69. PubMed ID: 6347618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of cinoxacin in elderly patients following repeated oral administration.
    Braga PC; Fraschini F; Scaglione F; Scarpazza G; Schiavi M; Ventura P
    Chemotherapy; 1987; 33(5):309-15. PubMed ID: 3665628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of outpatient urinary tract infections with cinoxacin.
    Jones GW; Mulholland SG
    J Fam Pract; 1980 Aug; 11(2):207-10. PubMed ID: 6997428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cinoxacin (Cinobac, Eli Lilly & Co.).
    Guay DR
    Drug Intell Clin Pharm; 1982 Dec; 16(12):916-21. PubMed ID: 6759090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinoxacin in urinary tract infections. Theoretical and practical considerations.
    Madsen PO; Frimodt-Møller N; Maigaard S; Nielsen OS; Rodriguez N; Welling PG
    Urology; 1981 May; 17(5):496-9. PubMed ID: 7233671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans.
    Brogard JM; Comte F; Lavillaureix J
    Eur J Drug Metab Pharmacokinet; 1983; 8(3):251-9. PubMed ID: 6653617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of recurrent urinary tract infections in premenopausal women by post-coital administration of cinoxacin.
    Pfau A; Sacks TG; Shapiro M
    J Urol; 1988 Jun; 139(6):1250-2. PubMed ID: 3286892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a new antihypertensive pyrrolyl pyridazinamine (MDL-899) in the rat and the dog.
    Assandri A; Bellasio E; Bernareggi A; Cristina T; Perazzi A; Odasso G
    Arzneimittelforschung; 1985; 35(2):508-13. PubMed ID: 3855234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinoxacin concentrations in plasma, urine and prostatic tissue after oral administration to man.
    Burt RA; Morgan T; Payne JP; Bonner RM
    Br J Urol; 1977 Apr; 49(2):147-52. PubMed ID: 858034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.